Published in J Pharmacol Exp Ther on March 20, 2014
Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. J Clin Oncol (2015) 1.41
Exploiting replicative stress to treat cancer. Nat Rev Drug Discov (2015) 1.27
PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med (2015) 1.16
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discov (2015) 1.06
Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Clin Cancer Res (2014) 0.97
Profile of veliparib and its potential in the treatment of solid tumors. Onco Targets Ther (2015) 0.89
PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma. Oncotarget (2015) 0.82
PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma. PLoS One (2014) 0.82
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. Oncotarget (2016) 0.82
Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo. Int J Mol Sci (2016) 0.81
Kinase-dead ATM protein is highly oncogenic and can be preferentially targeted by Topo-isomerase I inhibitors. Elife (2016) 0.80
Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer. Cancer Cell (2016) 0.79
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors. Clin Cancer Res (2016) 0.79
Trial watch - inhibiting PARP enzymes for anticancer therapy. Mol Cell Oncol (2015) 0.79
Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma. PLoS One (2015) 0.79
Abacavir, an anti-HIV-1 drug, targets TDP1-deficient adult T cell leukemia. Sci Adv (2015) 0.78
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer. Clin Cancer Res (2016) 0.78
Effects of Anticancer Drugs on Chromosome Instability and New Clinical Implications for Tumor-Suppressing Therapies. Cancer Res (2016) 0.78
Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors. Oncoimmunology (2015) 0.78
A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia. Clin Cancer Res (2016) 0.76
Telomere-Internal Double-Strand Breaks Are Repaired by Homologous Recombination and PARP1/Lig3-Dependent End-Joining. Cell Rep (2016) 0.76
Poly(ADP-ribose) polymers regulate DNA topoisomerase I (Top1) nuclear dynamics and camptothecin sensitivity in living cells. Nucleic Acids Res (2016) 0.76
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models. Mol Cancer (2017) 0.75
Tumor Cell Recovery from Senescence Induced by Radiation with PARP Inhibition. Radiat Res (2016) 0.75
Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development. Semin Oncol (2016) 0.75
Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer. NPJ Breast Cancer (2017) 0.75
Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse. Mol Cancer Res (2016) 0.75
Drugging the Cancers Addicted to DNA Repair. J Natl Cancer Inst (2017) 0.75
XRCC1-mediated repair of strand breaks independent of PNKP binding. DNA Repair (Amst) (2017) 0.75
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncol (2016) 0.75
Targeting DNA repair and replication stress in the treatment of ovarian cancer. Int J Clin Oncol (2017) 0.75
The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies. Cancer (2017) 0.75
Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions. Curr Med Chem (2016) 0.75
PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma. Oncogene (2017) 0.75
F10 cytotoxicity via topoisomerase I cleavage complex repair consistent with a unique mechanism for thymineless death. Future Oncol (2016) 0.75
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 19.13
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev (2006) 15.09
Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res (2010) 12.96
PARP inhibition: PARP1 and beyond. Nat Rev Cancer (2010) 6.70
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res (2006) 6.28
The DNA damage response and cancer therapy. Nature (2012) 5.25
Role of poly(ADP-ribose) formation in DNA repair. Nature (1992) 4.98
Increased ratio of targeted to random integration after transfection of chicken B cell lines. Cell (1991) 4.65
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A (2008) 4.61
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res (2012) 3.74
Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev (1997) 2.62
The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol (2011) 2.52
Drugging topoisomerases: lessons and challenges. ACS Chem Biol (2013) 2.46
Topoisomerase I poisoning results in PARP-mediated replication fork reversal. Nat Struct Mol Biol (2012) 2.44
Parp-1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells. EMBO J (2006) 1.97
Oxidative DNA damage repair in mammalian cells: a new perspective. DNA Repair (Amst) (2006) 1.85
Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. Nucleic Acids Res (2011) 1.76
Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition. Nat Struct Mol Biol (2013) 1.67
Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol Aspects Med (2013) 1.62
PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res (2012) 1.61
Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res (2010) 1.61
Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther (2013) 1.55
PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA. J Cell Biol (2008) 1.53
Advances in using PARP inhibitors to treat cancer. BMC Med (2012) 1.49
Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br J Cancer (2001) 1.42
The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks. Clin Cancer Res (2005) 1.35
Tyrosyl-DNA phosphodiesterase 1 (TDP1) repairs DNA damage induced by topoisomerases I and II and base alkylation in vertebrate cells. J Biol Chem (2012) 1.26
Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways. Mol Cancer Res (2009) 1.26
Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clin Cancer Res (2009) 1.25
Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. Breast Cancer Res Treat (2012) 1.23
AP endonuclease and poly(ADP-ribose) polymerase-1 interact with the same base excision repair intermediate. DNA Repair (Amst) (2004) 1.19
Poly(ADP-ribose) reactivates stalled DNA topoisomerase I and Induces DNA strand break resealing. J Biol Chem (2003) 1.12
A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity. PLoS One (2013) 1.11
PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage. Nucleic Acids Res (2014) 1.11
Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel. Mol Cancer Ther (2013) 1.09
Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br J Cancer (1995) 1.06
Predicting enhanced cell killing through PARP inhibition. Mol Cancer Res (2012) 1.01
Increased PARP-1 association with DNA in alkylation damaged, PARP-inhibited mouse fibroblasts. Mol Cancer Res (2012) 1.01
Mechanisms of resistance to PARP inhibitors--three and counting. Cancer Discov (2013) 0.93
In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells. Int J Radiat Oncol Biol Phys (2013) 0.91
The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines. Invest New Drugs (2012) 0.85
Formation and resealing of intercalator-induced DNA strand breaks in permeabilized L1210 cells without the stimulated synthesis of poly(ADP-ribose). J Biol Chem (1982) 0.85
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol (2011) 18.34
GammaH2AX and cancer. Nat Rev Cancer (2008) 9.77
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol (2009) 4.14
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res (2012) 3.74
Differential usage of non-homologous end-joining and homologous recombination in double strand break repair. DNA Repair (Amst) (2006) 3.61
Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping. Cancer Res (2003) 3.52
Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem (2003) 3.45
A critical role for the ubiquitin-conjugating enzyme Ubc13 in initiating homologous recombination. Mol Cell (2007) 3.23
Criteria for the use of omics-based predictors in clinical trials. Nature (2013) 3.15
DNA damage-dependent acetylation and ubiquitination of H2AX enhances chromatin dynamics. Mol Cell Biol (2007) 3.03
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol (2013) 2.94
Dual roles for DNA polymerase eta in homologous DNA recombination and translesion DNA synthesis. Mol Cell (2005) 2.88
The complexity of phosphorylated H2AX foci formation and DNA repair assembly at DNA double-strand breaks. Cell Cycle (2010) 2.84
Molecular interaction maps of bioregulatory networks: a general rubric for systems biology. Mol Biol Cell (2005) 2.82
Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov (2012) 2.74
Mutagenic processing of ribonucleotides in DNA by yeast topoisomerase I. Science (2011) 2.73
Inhibition of homologous recombination by the PCNA-interacting protein PARI. Mol Cell (2011) 2.61
Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription. Nat Cell Biol (2009) 2.60
CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res (2012) 2.57
DNA fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther (2009) 2.53
Compressing drug development timelines in oncology using phase '0' trials. Nat Rev Cancer (2007) 2.52
Cyclin-dependent kinases and cell-cycle transitions: does one fit all? Nat Rev Mol Cell Biol (2008) 2.48
Cleaving the oxidative repair protein Ape1 enhances cell death mediated by granzyme A. Nat Immunol (2003) 2.48
Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes. Cancer Res (2004) 2.42
The intra-S-phase checkpoint affects both DNA replication initiation and elongation: single-cell and -DNA fiber analyses. Mol Cell Biol (2007) 2.41
Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res (2003) 2.40
Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines. Mol Cancer Ther (2010) 2.38
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res (2013) 2.27
Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. Cancer Res (2007) 2.26
Single-stranded DNA-binding protein hSSB1 is critical for genomic stability. Nature (2008) 2.12
Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res (2010) 2.12
Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J Med Chem (2005) 2.12
Multiple roles of Rev3, the catalytic subunit of polzeta in maintaining genome stability in vertebrates. EMBO J (2003) 2.12
Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res (2002) 2.09
Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res (2011) 2.08
RAD18 and RAD54 cooperatively contribute to maintenance of genomic stability in vertebrate cells. EMBO J (2002) 2.06
AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin Cancer Res (2010) 2.06
Multiple repair pathways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate cells. Cancer Res (2005) 2.05
Ubiquitin-binding motifs in REV1 protein are required for its role in the tolerance of DNA damage. Mol Cell Biol (2006) 2.02
mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities. Mol Cancer Ther (2010) 2.00
Cediranib for metastatic alveolar soft part sarcoma. J Clin Oncol (2013) 1.99
Parp-1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells. EMBO J (2006) 1.97
Phase III clinical trial development: a process of chutes and ladders. Clin Cancer Res (2010) 1.97
Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res (2004) 1.96
XRCC3 and Rad51 modulate replication fork progression on damaged vertebrate chromosomes. Mol Cell (2003) 1.94
Cells deficient in the FANC/BRCA pathway are hypersensitive to plasma levels of formaldehyde. Cancer Res (2007) 1.92
Nbs1 is essential for DNA repair by homologous recombination in higher vertebrate cells. Nature (2002) 1.89
Centrosome amplification induced by DNA damage occurs during a prolonged G2 phase and involves ATM. EMBO J (2004) 1.89
CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer (2005) 1.89
Generation and iterative affinity maturation of antibodies in vitro using hypermutating B-cell lines. Nat Biotechnol (2002) 1.87
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol (2008) 1.87
Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol (2011) 1.87
Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann Neurol (2009) 1.86
Involvement of SLX4 in interstrand cross-link repair is regulated by the Fanconi anemia pathway. Proc Natl Acad Sci U S A (2011) 1.86
REV1 protein interacts with PCNA: significance of the REV1 BRCT domain in vitro and in vivo. Mol Cell (2006) 1.85
Designing phase 0 cancer clinical trials. Clin Cancer Res (2008) 1.85
Replication fork velocities at adjacent replication origins are coordinately modified during DNA replication in human cells. Mol Biol Cell (2007) 1.85
Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration. BMC Med (2013) 1.84
Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. Mol Cancer Ther (2009) 1.83
Thioredoxin-2 (TRX-2) is an essential gene regulating mitochondria-dependent apoptosis. EMBO J (2002) 1.82
Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry (2008) 1.82
Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth. Clin Cancer Res (2013) 1.80
Vertebrate POLQ and POLbeta cooperate in base excision repair of oxidative DNA damage. Mol Cell (2006) 1.79
A mutated EGFR is sufficient to induce malignant melanoma with genetic background-dependent histopathologies. J Invest Dermatol (2010) 1.78
Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. Nucleic Acids Res (2011) 1.76
Resistance to integrase inhibitors. Viruses (2010) 1.75
Poly(ADP-ribose) polymerase 1 accelerates single-strand break repair in concert with poly(ADP-ribose) glycohydrolase. Mol Cell Biol (2007) 1.75
Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts. Clin Cancer Res (2008) 1.70
Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies. Eur J Cancer (2008) 1.70
Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA lesions. DNA Repair (Amst) (2003) 1.70
Ataxia telangiectasia mutated activation by transcription- and topoisomerase I-induced DNA double-strand breaks. EMBO Rep (2009) 1.69
RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors. Cancer Res (2007) 1.68
Collaborative action of Brca1 and CtIP in elimination of covalent modifications from double-strand breaks to facilitate subsequent break repair. PLoS Genet (2010) 1.66
Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. J Clin Oncol (2004) 1.66
Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells. Clin Cancer Res (2010) 1.65
An essential role for Cdk1 in S phase control is revealed via chemical genetics in vertebrate cells. J Cell Biol (2007) 1.65
Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice. Mol Interv (2007) 1.64
DNA cleavage assay for the identification of topoisomerase I inhibitors. Nat Protoc (2008) 1.61
Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas. Cancer Biol Ther (2009) 1.60
A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res (2008) 1.60
Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent. Cell Cycle (2011) 1.60
Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat Rev Drug Discov (2010) 1.59
CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. BMC Genomics (2009) 1.58